Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FHKU3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,798
Award facts
- Contract value 100% obligated
- $29,797.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $29,797.50 to DMS Pharmaceutical Group Inc. for the supply of Entyvio 300 mg vials. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected as the awardee under a firm fixed-price contract with an ultimate completion date of January 5, 2026. The delivery order was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The place of performance is Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to provide recurring pharmaceutical supplies to military healthcare facilities worldwide. The parent contract, valued at $499,999,999, was awarded on November 13, 2025, and extends through December 31, 2036. DMS Pharmaceutical Group's established performance across a diverse portfolio of pharmaceuticals—including specialty biologics, oncology treatments, vaccines, and routine medications—demonstrates its capability to fulfill the specialized pharmaceutical requirements of the Department of Defense's global medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FHKU3?
SPE2DR26FHKU3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 2, 2026.
How much is contract SPE2DR26FHKU3 worth?
The government has obligated $29,798 on SPE2DR26FHKU3.
Is contract SPE2DR26FHKU3 an order under another contract?
Yes. SPE2DR26FHKU3 is a delivery order under SPE2DR25D9222, an indefinite delivery contract.
Was contract SPE2DR26FHKU3 competed?
The extent of competition for SPE2DR26FHKU3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award